Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial - 24/04/13
, Katrine Togsverd-Bo, MD, Stine Regin Wiegell, MD, Hans Christian Wulf, MD, DrMedSci
Reprint requests: Merete Haedersdal, MD, DrMedSci, PhD, Department of Dermatology D-42, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.Abstract |
Background |
Long-pulsed dye laser (LPDL)–assisted photodynamic therapy has been suggested to be superior to laser alone for acne vulgaris but no evidence is available.
Objective |
To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris.
Methods |
Fifteen patients received a series of 3 full-face LPDL treatments and half-face prelaser MAL treatments; the latter being randomly assigned to the left or right side.
Results |
Inflammatory lesions were reduced more on MAL-LPDL–treated than on LPDL-treated sides (week 4: 70% vs 50%, P = .003; week 12: 80% vs 67%, P = .004). Noninflammatory lesions reduced similarly. Patient satisfaction was slightly greater with MAL-LPDL versus LPDL treatments (scale 0-10: week 4: 7 vs 6, P = .034; week 12: 8 vs 7.5, P = .034). Fluorescence measurements detected photobleaching with MAL-LPDL (35.3%) and LPDL (7.3%) treatments (P < .001). Erythema, edema, and pustular eruptions intensified from MAL incubation. No patients experienced pigment changes or scarring.
Limitations |
The sample size was limited. The split-face design in this randomized controlled trial does not allow us to draw conclusions about the efficacy of the LPDL, only about the efficacy of MAL-LPDL compared with LPDL alone.
Conclusions |
MAL-LPDL is slightly superior to LPDL for the treatment of inflammatory acne.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ALA, IPL, LPDL, MAL-LPDL, PDL, PDT, RCT
Plan
| Funding sources: None. |
|
| Disclosure: V-beam Perfecta was borrowed from Candela Laser Corporation, Wayland, Mass (M. H.). Lectures given for PhotoCure as part of an educational program (by M. H., S. R. W., H. C. W.). |
Vol 58 - N° 3
P. 387-394 - mars 2008 Retour au numéro
Article précédent
- Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
- Putao Cen, Madeleine Duvic, Philip R. Cohen, Razelle Kurzrock
- Subcutaneous efalizumab is not effective in the treatment of alopecia areata
- Vera H. Price, Maria K. Hordinsky, Elise A. Olsen, Janet L. Roberts, Elaine C. Siegfried, Elyse S. Rafal, Neil J. Korman, Basel Altrabulsi, Hoi M. Leung, Marvin R. Garovoy, Ivor Caro, David A. Whiting
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?